RESCAP prevents and treats acute Ischemic Injury and subsequent complications like Acute Kidney Injury and capillary leak symptoms.
Applications of RESCAP in e.g. Cardiothoracic Surgery, Solid Organ Transplant Surgery, Burn wound trauma and COVID-19
APPIRED III, a global clinical phase 2b/3 in cardiothoracic surgery is actively recruiting patients.
“Major surgeries and transplantations are to be free from morbidity and mortality resulting from ischemic injury.”
Reducing peri-and post-surgical complications will improve general health, post-surgical quality of life and reduce overall healthcare cost
Meet Alloksys and Amrif
How we work together with clinicians, hospitals and other institutions to help patients with unmet medical need diseases.
In this video:
- What is RESCAP?
- Our research on protecting barriers and anti-inflammatory action
- More information on our partnerships to transfer our products to the market
We are very proud to work with:
Participating Clinicians and clinical centers and Aix Scientifics as global CRO in ongoing and planned clinical trials as well as investors and Dutch RVO innovation credit facility, Health Holland and the Burn wound foundation and TKI support for specific clinical projects.
May 2020 COVID19 RESCAP intervention obtains fast track approval
RESCAP intervention in critically ill SARS-COV2 infected patients admitted to ICU has been approved through the Dutch Health Ministry delegated VUmc Medical Ethical Board in
RESCAP in severe burn wound trial
Alloksys’s RESCAP platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP administration is expected to significantly attenuate the overall
January 2020 APPIRED III
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
Clinical Data APPIRED I and APPIRED II are basis for breakthrough
Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the
Update December 2019: Solid Organ Transplantation Study well on its way
After approval was obtained in October 2018, the kidney transplantation study with RESCAP platform technology under supervision of PI Dr Joost van der Heijden from
Sister Company AMRIF readying up for clinical trial in chronic inflammatory disease
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. Among these diseases are unmet medical need applications in Neurodegenerative